In trials that adopted anti-PD-1/PD-L1 as the first line of therapy, induction chemotherapy combined with radiotherapy was the predominant choice, employed in 25 trials, highlighting its significance as an initial strategy in NPC treatment. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.